# Translational Study of Cardiac Dysfunction

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA AT DAVIS · 2022 · $678,672

## Abstract

Abstract
 Atrial fibrillation (AF) represents one of the most common arrhythmias clinically and is associated with a
significant increase in morbidity and mortality, yet, current treatment paradigms remain inadequate. Treatment
with conventional antiarrhythmic drugs generally carries a high risk of proarrhythmia. Moreover, prevalence of
AF is increasing due to the aging population. We were the first to demonstrate beneficial effects of a novel
class of anti-inflammatory agent, soluble epoxide hydrolase (sEH) inhibitors, in clinically relevant models of
cardiac hypertrophy and failure. Treatment with sEH inhibitors (sEHIs) results in the prevention of ventricular
myocyte hypertrophy and electrical remodeling in pressure overload and MI models. During the last funding
cycle, we demonstrate that treatment with sEHIs prevents cardiac fibroblast (CF) proliferation, fibrosis, adverse
cardiac remodeling, and AF. These results demonstrate broader salutary effects in cardiac remodeling (not
limited to myocyte hypertrophy alone) of this novel class of compounds. The goal of the competing renewal is
to test the hypothesis that an increase in the level of endogenous EETs by sEHIs represents a completely
unexplored avenue to modify atrial fibrosis by reducing CF proliferation and activation. The proposal
represents a bench-to-bedside multidisciplinary study to determine the mechanism and efficacy of using sEHIs
for the treatment of AF.

## Key facts

- **NIH application ID:** 10341069
- **Project number:** 5R01HL085727-12
- **Recipient organization:** UNIVERSITY OF CALIFORNIA AT DAVIS
- **Principal Investigator:** Nipavan Chiamvimonvat
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $678,672
- **Award type:** 5
- **Project period:** 2008-02-01 → 2025-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10341069

## Citation

> US National Institutes of Health, RePORTER application 10341069, Translational Study of Cardiac Dysfunction (5R01HL085727-12). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10341069. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*